Cargando…

Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study

Detalles Bibliográficos
Autores principales:	Schetelig, Johannes, Hoek, Jennifer, Stilgenbauer, Stephan, Middeke, Jan Moritz, Andersen, Niels Smedegaard, Fox, Christopher P., Lenhoff, Stig, Volin, Liisa, Shimoni, Avichai, Schroyens, Wilfried, van Gelder, Michel, Bunjes, Donald, van Biezen, Anja, Baldauf, Henning, de Wreede, Liesbeth C., Tournilhac, Olivier, Kröger, Nicolaus, Yakoub-Agha, Ibrahim, Dreger, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732263/ https://www.ncbi.nlm.nih.gov/pubmed/34773090 http://dx.doi.org/10.1038/s41409-021-01524-2

Ejemplares similares

Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study
por: Schetelig, Johannes, et al.
Publicado: (2020)

Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party
por: Schetelig, Johannes, et al.
Publicado: (2020)

Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party
por: Schetelig, Johannes, et al.
Publicado: (2021)

Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia
por: Schetelig, Johannes, et al.
Publicado: (2018)

Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia
por: Schetelig, Johannes, et al.
Publicado: (2021)

Corrigendum: Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia
por: Schetelig, Johannes, et al.
Publicado: (2021)

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
por: Robin, Marie, et al.
Publicado: (2019)

Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation
por: Schmid, Christoph, et al.
Publicado: (2018)

Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation
por: Shimoni, Avichai, et al.
Publicado: (2016)

Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT
por: Cremers, E. M. P., et al.
Publicado: (2016)

The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT
por: Tournilhac, Olivier, et al.
Publicado: (2023)

Multiple imputation for cause-specific Cox models: Assessing methods for estimation and prediction
por: Bonneville, Edouard F, et al.
Publicado: (2022)

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
por: McLornan, Donal P., et al.
Publicado: (2019)

Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor
por: Morris, Curly, et al.
Publicado: (2019)

Integrating relative survival in multi-state models—a non-parametric approach
por: Manevski, Damjan, et al.
Publicado: (2022)

Regulatory T Cells in Allogeneic Stem Cell Transplantation
por: Michael, Maria, et al.
Publicado: (2013)

Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study
por: Greinix, Hildegard T., et al.
Publicado: (2021)

Competing-risk outcomes after hematopoietic stem cell transplantation from the perspective of time-dependent effects
por: Fuerst, Daniel, et al.
Publicado: (2018)

Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT
por: Gilleece, Maria H., et al.
Publicado: (2021)

Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions
por: Danylesko, Ivetta, et al.
Publicado: (2012)

Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT
por: Shimoni, Avichai, et al.
Publicado: (2019)

Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey
por: Sellner, Leopold, et al.
Publicado: (2020)

Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey
por: Sellner, Leopold, et al.
Publicado: (2021)

Intensive immunosuppression followed by autologous hematopoietic stem cell transplantation for the treatment of multiple sclerosis
por: Lycke, Jan, et al.
Publicado: (2020)

Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase
por: Alakel, Nael, et al.
Publicado: (2017)

Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience
por: Chihara, Dai, et al.
Publicado: (2022)

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT
por: Gagelmann, Nico, et al.
Publicado: (2018)

Primary Cancer Matters in Therapy-related Myeloid Neoplasm Patients Receiving Allogeneic Hematopoietic Cell Transplantation: A Study From the Chronic Malignancies Working Party of the EBMT
por: Robin, Marie, et al.
Publicado: (2023)

Melphalan 140 mg/m(2) or 200 mg/m(2) for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party
por: Auner, Holger W., et al.
Publicado: (2018)

Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT
por: Chalandon, Yves, et al.
Publicado: (2022)

Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation
por: Gagelmann, Nico, et al.
Publicado: (2019)

Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT
por: Raj, Kavita, et al.
Publicado: (2022)

P1398: AXICABTAGENE CILOLEUCEL VERSUS TISAGENLECLEUCEL CAR-T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Gagelmann, Nico, et al.
Publicado: (2023)

Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT
por: Drozd-Sokołowska, Joanna, et al.
Publicado: (2022)

Comparison of Allogeneic Stem Cell Transplantation and Non-Transplant Approaches in Elderly Patients with Advanced Myelodysplastic Syndrome: Optimal Statistical Approaches and a Critical Appraisal of Clinical Results Using Non-Randomized Data
por: Brand, Ronald, et al.
Publicado: (2013)

Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study
por: Waszczuk-Gajda, Anna, et al.
Publicado: (2022)

Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT
por: Poiré, Xavier, et al.
Publicado: (2020)

Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling
por: Lawless, Sarah, et al.
Publicado: (2022)

Hydroxychloroquine in Covid-19: Does the end justify the means?
por: Yakoub-Agha, Ibrahim
Publicado: (2020)

Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT
por: Penack, Olaf, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_iv5j8nsblvj7s3gtkqqfjom3kg